Brought to you by 
Takeda, LegoChem research ADCs; Takeda later gains rights for multiple immuno-oncology targets in $411mm license deal
16 Nov 2021
Executive Summary
LegoChem Biosciences Inc. and Takeda Pharmaceutical Co. Ltd. (through its Takeda Oncology/Millennium Pharmaceuticals unit) will together research and develop next-generation antibody-drug conjugates (ADCs) for cancer.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Immuno-Oncology
-
Large Molecule
- Antibodies
-
Drug Discovery Tools
- ADMET
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Takeda, LegoChem research ADCs; Takeda later gains rights for multiple immuno-oncology targets in $411mm license deal
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice